Amgen Inc.

Chimeric Receptors to STEAP1 and Methods Of Use Thereof

SOLID FORMS OF MACROCYCLIC COMPOUNDS AND USES THEREOF

TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF

SOLID STATE FORMS

SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS

METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS

COMPOSITIONS OF ANTI-INTERLEUKIN 12/INTERLEUKIN 23 ANTIBODY

MACROCYCLIC COMPOUNDS AND METHODS OF USE

METHODS FOR TREATING OBESITY

COMPOUNDS AS MODULATORS OF STAT6 AND USES THEREOF

DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODS

Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction

PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF

HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF

5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS

PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN

MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS

Damper Overfill Chamber to Increase Functional Robustness Regarding Variance in Parts and Processes

CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE

COMBINATION THERAPIES COMPRISING T-CELL REDIRECTING THERAPIES AND AGONISTIC ANTI-IL-2R ANTIBODIES OR FRAGMENTS THEREOF

USE OF ONCOLYTIC VIRUSES, ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR, FOR THE TREATMENT OF CANCER

KIF18A INHIBITORS

SEQUENTIAL DIGESTION OF POLYPEPTIDES FOR MASS SPECTROMETRIC ANALYSIS

MAGEA4 SPECIFIC T CELL RECEPTORS

METHODS OF DETECTING OFF-TARGET BINDING OF PROTEINS

ANTI-DRUG ANTIBODY ASSAYS

MULTISPECIFIC MOLECULES FOR CLEARANCE OF IMMUNOGLOBULINS IN THE TREATMENT OF AUTOANTIBODY-INDUCED DISEASES

METHOD OF CONJUGATION OF CYS-MABS

Synthesis of KRAS G12C Inhibitor Compound

DRUG DELIVERY DEVICE

DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS

COMBINATION THERAPY METHODS WITH T-CELL ENGAGING MOLECULES FOR TREATMENT OF PROSTATE CANCER

METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS

SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME

METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS

SOTORASIB DOSING REGIMEN

SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND

SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND

Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions

METHODS OF SCREENING FOR PEPTIDE-HLA CLASS I ALLOREACTIVITY

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME

BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF

METHOD FOR ENHANCING PRODUCTION OF GENETICALLY ENGINEERED AUTOLOGOUS T CELLS

HOMOGENEOUS ANTIBODY POPULATIONS

REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS

DATA AUGMENTATION AND ENCODING OF MULTI-CHAIN PROTEIN STRUCTURES

TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF

MAGEB2 BINDING CONSTRUCTS

FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME

STABILIZATION OF FC-CONTAINING POLYPEPTIDES

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

TORQUE DRIVEN DRUG DELIVERY DEVICE

METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS

RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF

AGONISTIC ANTI-IL-2RBG HEAVY-CHAIN ANTIBODIES

NEEDLE SHIELD REMOVERS, DRUG DELIVERY DEVICES, AND RELATED METHODS

LYOPHILIZED VIRUS FORMULATIONS

MACROCYCLIC COMPOUNDS AND METHODS OF USE

PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR

INTENSIFIED ULTRAFILTRATION/DIAFILTRATION PROCESSES

MAGEB2 BINDING CONSTRUCTS

HETEROMULTIMER BINDING DLL3 AND CD3

CANNABINOID TYPE 1 RECEPTOR BINDING PROTEINS AND USES THEREOF

SUSTAINABLE AND MODULAR PACKAGING SYSTEMS FOR CONTAINERS FOR PHARMACEUTICAL USE

GLUCAGON RECEPTOR AGONISTS AND CONJUGATES TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANTAGONISTS

METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS

DRUG DELIVERY DEVICE

METHOD FOR EXTERNAL STERILIZATION OF DRUG DELIVERY DEVICE

PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES

COMPLEMENT-DEPENDENT CYTOTOXICITY METHODS

SYSTEMS AND METHODS FOR CONFIGURING A ROBOT TO INTERFACE WITH EQUIPMENT

DRUG DELIVERY DEVICE

TREATMENT OF SOLID TUMORS

MACROCYCLIC COMPOUNDS AND METHODS OF USE

METHODS AND SYSTEMS FOR VISCOSITY PREDICTION AND PROTEIN ENGINEERING

Combinations of a B-RAF Inhibitor and an Anti-EGFR Antibody for the Treatment of Cancer

ANTI-PD-1 ANTIBODY FORMULATIONS

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND

BISPECIFIC ANTIBODIES WITH CLEAVABLE C-TERMINAL CHARGE-PAIRED TAGS

TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE

OPTIMIZED TRANSFECTION PROTOCOL

MODULAR VECTOR (MODVEC) SYSTEM: A PLATFORM FOR CONSTRUCTION OF NEXT GENERATION EXPRESSION VECTORS

LIQUID PHASE PEPTIDE SYNTHESIS METHODS

A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE

QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS

SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND

METHODS OF PREPARING HIGH CONCENTRATION LIQUID DRUG SUBSTANCES

ANTI-CCR8 ANTIBODIES AND USES THEREOF

ANTI-TNF ALPHA ANTIBODY FORMULATIONS

CONTAINERS AND SYSTEMS FOR USE DURING EXTERNAL STERILIZATION OF DRUG DELIVERY DEVICES

AUTOMATED SYSTEMS AND METHODS FOR FOIL PACKAGING COMPONENTS

QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF